Myricx Bio, a UK biotech company developing a novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), have entered into a license agreement under which Myricx will have exclusive access to an antibody discovered based on WuXi Bio’s integrated technology platforms.   Myricx will develop the antibody into a first-in-class ADC based on its NMTi paylo...